City Therapeutics, Inc. (CTY)

City Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

City Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	14.34	13.56	2.78
Revenue Growth	-	388.19%	-
Gross Profit	14.34	13.56	2.78
Selling, General & Admin	-	15.06	6.19
Research & Development	-	58.42	25.68
Operating Expenses	-	73.48	31.87
Operating Income	-84.46	-59.92	-29.09
Interest Expense (Income)	-0.63	-1.95	-1.95
Other Expense (Income)	3.84	0.53	0.7
Pretax Income	-87.67	-58.51	-27.84
Net Income	-87.67	-58.51	-27.84

Additional Metrics

Year Ending	TTM	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-80.75	-44.02	-23.93
Free Cash Flow Growth	-	-	-
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-588.90%	-441.84%	-1047.16%
Profit Margin	-611.25%	-431.39%	-1002.02%
Free Cash Flow Margin	-563.00%	-324.55%	-861.34%
EBITDA	-86.84	-59.28	-29.36
EBITDA Margin	-605.46%	-437.13%	-1056.91%
Depreciation & Amortization	1.46	1.17	0.42
EBIT	-88.3	-60.46	-29.79
EBIT Margin	-615.66%	-445.77%	-1072.17%